<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-2-17-02-2026-shutterstock_2249605625-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-2-17-02-2026-shutterstock_2249605625-430x241.jpg"/>
                                    
                                    <figcaption>Both companies share the goal of providing innovative treatments to improve quality of life for women with gynaecological conditions. Credit: Peakstock / Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                             
     
<p>Teijin Pharma has signed a joint research agreement with Tokyo-based Aska Pharmaceutical to develop small-molecule drug candidates for gynaecological diseases.</p>



<p>The collaboration aims to expedite early-stage drug discovery focused on innovative therapeutics, using Teijin Pharma’s expertise in computer-aided drug design (CADD) and AI.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - GSK-4381562 in Endometrial Cancer </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - INCB-123667 in Endometrial Cancer </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>Under the agreement, both companies will focus on identifying “hit” compounds that interact with specific molecular targets.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>These initial compounds will undergo further optimisation to establish the desired efficacy, pharmacokinetic properties, and safety required for potential drug development.</p>



<p>Teijin Pharma is advancing its drug candidate discovery process by enhancing simulation accuracy and predictive modelling, resulting in a research platform that shortens timelines and raises the probability of success in drug development.</p>



<p>Aska Pharmaceutical brings experience grounded in addressing real-world clinical needs, particularly in women’s health, and has developed a portfolio focused on unmet medical requirements in the field.</p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>The company has developed a wide range of products to support women at various stages of life.</p>



<p>The partnership will combine Teijin Pharma’s advanced drug discovery technologies with Aska Pharmaceutical’s clinical expertise in gynaecological disease evaluation.</p><div id="slot-two"></div>



<p>Both companies share the goal of providing innovative treatments to improve the quality of life for women with gynaecological conditions.</p>



<p>Aska Pharmaceutical specialises in three areas: urology, internal medicine (gastroenterology and thyroid), and obstetrics and gynaecology.</p>



<p>Teijin operates across high-performance materials and healthcare solutions worldwide, working with partners to deliver solutions aligned with its long-term vision.</p>



<p>Teijin recently submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency seeking manufacturing and marketing approval for lonapegsomatropin, a prodrug of somatropin, which is administered once weekly.</p>
<div id="slot-three"></div><p></p>



<div>
    
</div>

3401

4886

<p>Teijin Pharma has entered a joint research agreement with Aska Pharmaceutical to co-develop small-molecule drug candidates for gynaecological diseases. The collaboration aims to leverage Teijin's expertise in computer-aided drug design and AI to expedite early-stage drug discovery. Both companies will focus on identifying compounds that interact with specific molecular targets, optimizing them for efficacy and safety. This partnership seeks to improve the quality of life for women with gynaecological conditions, combining Teijin's advanced drug discovery technologies with Aska's clinical expertise.</p>

Teijin and Aska Pharmaceutical to co-develop gynaecological drugs